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Abstract: Smoking cessation remains a health promotion target. Applying the Transtheoretical Model
to Australian Burden of Obstructive Lung Diseases (BOLD) data, we examined differences in stages of
change (SoC) and readiness to quit decisional behaviours. Factors were identified likely to influence
readiness of smokers, ≥40 years old, to quit. Analysis was restricted to current smokers classified to
one of three stages: pre-contemplation (PC), contemplation (C) or preparation (P) to quit. Their ability
to balance positive and negative consequences was measured using decisional balance. Among 314
smokers, 43.0% females and 60.8% overweight/obese, the distribution of SoC was: 38.1% PC, 38.3% C
and 23.5% P. Overweight/obesity was associated with readiness to quit in stages C and P and there
were more negative than positive attitudes towards smoking in those stages. Males were significantly
heavier smokers in PC and C stages. Females used smoking cessation medication more frequently
in PC stage, were more embarrassed about smoking and had greater negative reinforcements from
smoking. Age started smoking and factors related to smoking history were associated with readiness
to quit and increased the odds of being in stage C or P. An overweight/obese smoker was likely to be
contemplating or preparing to quit. In these stages, smokers have more negative attitudes toward
smoking. Starting smoking later, taking advice on cessation from health providers and using quit
medications indicate increased readiness to quit. Evaluating these factors in smokers and developing
cessation gain-framed messages may prove useful to healthcare providers.
Keywords: stages of change; decisional balance; smoking cessation; gender difference; Burden of
Obstructive Lung Disease (BOLD)
1. Introduction
Tobacco use is a global epidemic with related diseases estimated to kill over eight million people
a year globally, which are mostly avoidable [1]. Unfortunately, the true effect on mortality is not
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immediate—usually taking years to manifest, making it a slow killer [2]. In Australia, smoking was
reported to be the cause of 13.3% of deaths in 2015 and causally linked to the burden of 39 diseases [3].
Men and women are affected differently by tobacco use and tobacco messaging and smoking rates
differ between men and women. There is evidence of reduced levels of pulmonary function in male
smokers, higher smoking prevalence among males, while women have higher quit rates, lower quit
maintenance and use more strategies to cope with smoking temptation [4,5], In Australia, smoking is
the largest single preventable cause of death and disease accounting for 9.3% of the total burden of
disease [3,6]. Australia’s Health 2018, reported daily smoking rates had decreased from 24.0% to 12.0%
between 1991 and 2016 [6]. Smoking is a modifiable risk factor and prevention and cessation remains
an important public health issue globally.
Cessation advice when tailored to an individuals’ readiness to quit, could be more effective than
just providing broad, non-specific advice. For early cessation to be achieved, different strategies that
appeal to behaviour change must be employed. According to Velicer et al., as much as 50% of premature
mortality can be attributed to health behaviours and understanding those behaviours is critical to
interventions [7]. The Transtheoretical Model (TTM) is widely used for examining health behaviour
change in smokers by examining their stages of change (SoC) and decisional balance (DB) [8–11].
It is an integrative behaviour change model for intentional change focused on the decision making
of individuals [7]. This concept the—“stages of change” forms a key element of the TTM, where a
person cycles through six stages of change: pre-contemplation, contemplation, preparation, action,
maintenance and termination [8,12].
Targeting cessation advice may be aided by understanding smokers’ SoC, their DB, that is,
how the potential gains (pros) and losses (cons) are balanced to influence a decision [8,13]. Studies
using the first three stages, pre-contemplation, contemplation and preparation, have reported most
smokers are in the precontemplation and contemplation stages compared to those preparing to quit.
The distribution for these varies with the US having 40%-40%-20%, Europe 70%-20%-10% and Australia
55%-34%-11% [8–10]. Prevalence among the stages is more heavily weighted to those not thinking
about quitting and those likely to quit in the next six months. Using the concept of stages, different
programmes have been implemented to target behaviour change, primarily targeting intervention
such as, for example, personalised smoking cessation for callers to the Australian Quitline, stage-based
self-help programmes or individual counselling [14,15]. These types of interventions have mixed
results of being neither more nor less successful than standard interventions. However, Borland et al.
highlight that in using the TTM, tailored schedules for feedback can be created to provide intensive
support to the smoker and can assist movement through the stages to stable cessation state [15].
The TTM is a popular model and one of the many theories and theoretical constructs that has been
applied to smoking cessation and other problem behaviours [3]. However, it is not without its critics.
The arguments against, claim that the definitions used for the stages are arbitrary, categories are not
qualitatively distinct and there was no peer-review of the development of the model [16,17]. As with
most models, there are limitations and the TTM was not designed to be definitive or prescriptive.
However, as a public health tool, TTM can be used to generate possible intervention strategies using
stage-based activity promotion to address behaviour change at various stages of the decision-making
process. Smoking, as with other health behaviours is complex and there are no “gold standard”
algorithms for staging [18].
Despite decreasing smoking rates, Australia continues to make smoking cessation a key public
health focus. TTM has come under criticism in the past decade, with for example Borland et al.
“tweaking” the TTM to reconceive the stages of precontemplation and contemplation by considering
important perspectives on change [19]. Nonetheless, these constructs still provide meaning full
information for process change in smoking cessation. Our study was unable to capture the reconceived
stages outlined by Borland et al. and thus examined factors likely to influence readiness to quit, readiness
to quit decisional behaviours, change in SoC distribution and presence of differing demographics
among Australian men and women who currently smoke.
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2. Materials and Methods
2.1. Study Population
The study methodology for the Australian Burden of Obstructive Lung Disease (BOLD) study
has been outlined elsewhere [20,21]. Briefly, the study comprised a representative sample of
non-institutionalized Australians aged ≥40 years, residing in six locations across the country. Electoral
rolls were used to obtain a sex-stratified, simple random sample of participants in all but one site.
Sites were not randomly selected but chosen to reflect the country’s sociodemographic and geographic
diversity [21]. A total of 3357 participated in the study but this analysis will focus on a subset of 314
participants who reported current cigarette smoking.
The BOLD-Australia Study was approved by the Human Research Ethics Committee of the
University of Sydney (ref. no. 12-2006/9724). All sites obtained local ethics approval and participants
provided written informed consent.
2.2. Measures
2.2.1. Demographics and Smoking Characteristics
The BOLD study questionnaire collected information such as gender, age, education, weight and
height, body mass index (BMI); smoking history: status, number of cigarettes per day, ages of starting
and stopping, quit attempts, quit advice and quit medication; respiratory symptoms: cough, phlegm,
wheeze and shortness of breath. Smoking status was established when participants were asked “Have
you ever smoked cigarettes?” A “Yes” response meant “more than 20 packs of cigarettes in a lifetime
or more than 1 cigarette each day for a year.” Ever smokers were further classified into current and
former smokers by the age they stopped smoking.
2.2.2. Stages of Change
The BOLD study used a specific questionnaire for stages of change among current smokers.
The questionnaire only focused on three TTM stages. The revised algorithm for three of the five stages
was used: pre-contemplation, contemplation and preparation [8,22]. Responses to “Are you seriously
thinking of quitting smoking?” were used to group participants into the three stages as follows:
• Pre-contemplation: “No, not thinking of quitting” (individual is not ready/not thinking about
making a change)
• Contemplation: “Yes, within the next 6 months” (individual thinking about making a change but
not in the immediate future)
• Preparation: “Yes, within the next 30 days” (individual ready to change and intends to try to
make a change in the immediate future and may be making small preparatory changes)
2.2.3. Decisional Balance
The pros and cons for the DB were measured using a modified short form of the Smoking
Decisional Balance Scale questionnaire [13]. This included responses to:
• Pros: “Smoking cigarettes relieves tension; Smoking helps me concentrate and do better work;
I am relaxed and therefore more pleasant when smoking”
• Cons: “I’m embarrassed to have to smoke; My cigarette smoking bothers other people; People
think I am foolish for ignoring the warnings about cigarette smoking”
A pro score and con score was calculated based on the mean of the 5-point Likert response scale
(“1 = Not important” to “5 = Extremely important”). The DB was calculated as the difference between
these mean pros and cons scores. Therefore, more positive or negative scores indicated positive or
negative attitudes among smokers on the pro/con balance scale.
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2.3. Statistical Analysis
Descriptive statistics were used to describe demographic and smoking characteristics. Differences
between the SoC and gender differences within the stages were assessed using chi-square, t-test,
Kruskal-Wallis and analysis of variance (ANOVA). Tukey’s adjustments were made for multiple
comparisons. Multinomial logistic regression was used to determine factors that predicted smokers’
readiness to quit.
Analysis for the DB was affected by missing values. One study site, with 59 participants,
was excluded as no data were collected. The demographic and smoking history profiles for this
excluded group were not significantly different from other smokers, except for age where the excluded
group was younger (51 vs. 54 years; p = 0.02). For this variable there were an additional 19 cases
missing completely at random. Imputation using Expectation-Maximization was conducted and
analysis performed on 255 cases [23].
For the logistic regression, the sub-sample of 255 cases with complete DB data was used.
Purposeful selection was used for model building [24]. Models were fitted with one covariate at a
time and assessed for fit. Checks were done for multicollinearity, correct ratio of cases to variables
and outliers. Seven outlying cases were filtered out after examination of differences in classification
accuracy. A multinomial logistic model was fitted to determine the odds of membership in a
SoC. Pre-contemplation was used as the reference category when observing/predicting membership
among the SoC. Two models were developed to compare individuals in the contemplation stage and
preparation stage with those in the pre-contemplation stage. Usefulness of the model was determined
by improvement in accuracy over chance alone. Smokers were in the contemplation or preparation
stage if the OR > 1.0 and in the pre-contemplation stage if the OR < 1.0.
Level of statistical significance was set at 0.05, all tests were two-sided and SPSS (ver20, IBM,
Armonk, NY, USA) was used to conduct the analysis.
3. Results
3.1. Demographics, Health Characteristics and Stages of Change
Of the 314 smokers, 43.0% were females, 94.6% Caucasian and 85.0% of working age. Participants
ranged in age from 40-89 years (mean = 53, SD = 10) and the majority (60.8%) had a BMI > 25 kg/m2.
Approximately 69.9% had 7–12 years of schooling and 26.6% over 12 years.
Respiratory symptoms were common: 45.2% usually had a cough without a cold; 34.7% usually
brought up phlegm in the absence of a cold; 51.3% suffered from wheeze within the last 12 months;
and 30.6% had dyspnoea on moderate exertion.
Smoking started at a mean age of 18 (SD = 5) years, with participants smoking a median of
15 (IQR: 10–20) cigarettes per day. Quit attempts of at least 24 hours had been made on average
once (IQR: 0–3) in the previous 12 months. The majority (73.2%) indicated that they had previously
received quit advice from a physician or other health care provider, about a quarter (25.5%) of whom
had received the advice within the last 12 months. Nearly two fifths (36.9%) had used some type of
medication in their previous quit attempts.
Approximately 38.1% of smokers were in pre-contemplation, 38.3% in contemplation and 23.5% in
preparation stages (Table 1). The distributions of SoC among males and females showed no significant
differences. Demographic, respiratory and smoking characteristics were examined across the SoC
and within each stage by gender (Table 1). There were no significant gender differences within the
SoC, nor overall significant associations observed between the SoC and the other demographic and
health indicators except for BMI. BMI showed a significant difference between stages (F2,305 = 3.68,
p= 0.03) with those overweight being more in the contemplation and preparation stages compared to
pre-contemplation (p = 0.03 and p = 0.14 respectively).
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Table 1. Demographics, Respiratory and Smoking Characteristics by Stages of Change and Gender, Burden of Obstructive Lung Diseases (BOLD)-Australia Study.
Characteristics
Stages of Change
Pre-Contemplation (n = 118) Contemplation (n = 119) Preparation (n = 73)
M F p All M F p All M F p All
Age (mean, SD) 54.9 (10.0) 53.1 (10.2) 0.35 54.1 (10.1) 52.4 (8.6) 55.1 (9.6) 0.12 53.5 (9.1) 53.9 (11.2) 52.0 (8.4) 0.42 53.0 (10.0)
BMI (mean, SD) 25.1 (4.2) 26.3 (5.1) 0.15 25.6 (4.6) 27.6 (4.4) 26.8 (5.2) 0.38 27.3 (4.7) 27.9 (5.7) 26.1 (5.2) 0.16 27.0 (5.5) ‡
Years of Schooling (mean, SD) 11.7 (3.0) 11.2 (2.7) 0.41 11.5 (2.8) 11.4 (3.0) 11.9 (2.9) 0.43 11.4 (2.9) 11.5 (2.9) 11.8 (3.1) 0.68 11.6 (3.0)
Respiratory Symptoms (n, %)
Cough 35.0 (52.2) 25.0 (49.0) 0.73 60.0 (50.8) 32.0 (45.1) 18.0 (37.5) 0.41 50.0 (42.0) 16.0 (42.1) 13.0 (37.1) 0.66 29.0 (39.7)
Phlegm 28.0 (41.8) 15.0 (29.4) 0.17 43.0 (36.8) 29.0 (40.8) 13.0 (27.1) 0.12 42.0 (35.3) 14.0 (36.8) 8.0 (22.8) 0.19 22.0 (30.1)
Wheeze in last 12 months 31.0 (46.3) 23.0 (45.1) 0.90 54.0 (45.8) 43.0 (60.6) 26.0 (54.2) 0.49 69.0 (58.0) 19.0 (50.0) 18.0 (51.4) 0.90 37.0 (50.7)
Dyspnoea on exertion 15.0 (23.8) 17.0 (34.0) 0.23 32.0 (27.4) 21.0 (31.8) 22.0 (46.8) 0.11 43.0 (38.1) 9.0 (24.3) 11.0 (34.4) 0.36 32.0 (28.3)
Smoking History
Age started (mean, SD) 16.4 (3.0) 17.6 (4.2) 0.06 16.9 (3.6) 18.1 (4.7) 17.7 (4.2) 0.63 18.0 (4.5) 20.3 (7.7) 19.3 (6.7) 0.55 19.8 (7.2) ‡
Cigarettes/day (median, IQR) 20.0 (10.0, 25.0) 12.0 (5.0, 20.0) 0.02 † 16.7 (7.0, 25.0) * 20.0 (12, 25) 15.0 (10.0, 20.0) 0.04 † 20.0 (10.0, 25.0) 13.5 (5.0, 20.0) 10.0 (7.0, 15.0) 0.55 10.0 (6.0, 20.0)
Pack-Years (median, IQR) 30.2 (18.0, 47.2) 21.4 (5.5, 38.9) 0.01 † 26.8 (12.2, 45.5) * 30.4 (18.7,44.3) 24.3 (14.2, 41.1) 0.17 28.0 (17.2, 41.6) 20.0 (8.2, 46.3) 17.2 (10.1, 24.9) 0.37 18.1 (8.7, 37.4) ‡
Quit Activity (n, %)
Physician quit advice 52.0 (78.8) 32.0 (64.0) 0.08 84.0 (72.4) 55.0 (20.3) 35.0 (74.5) 0.51 90.0 (77.6) 28.0 (73.7) 25.0 (71.4) 0.83 53.0 (72.6)
Int. J. Environ. Res. Public Health 2019, 16, x FOR PEER REVIEW  5 of 12 
 
Table 1. Demographics, Respiratory and Smoking Characteristics by Stages of Change and Gender, Burden of Obstructive Lung Diseases (BOLD)-Australia Study. 
Characteristics  
Stages of Change  
Pre-Contemplation (n = 118) Contemplation (n = 119) Preparation (n = 73) 
M F p All M F p All  M F p All 
Age (mean, SD) 54.9 (10.0) 53.1 (10.2) 0.35 54.1 (10.1) 52.4 (8.6) 55.1 (9.6) 0.12 53.5 (9.1) 53.9 (11.2) 52.0 (8.4) 0.42 53.0 (10.0) 
BMI (mean, SD)  25.1 (4.2) 26.3 (5.1) 0.15 25.6 (4.6) 27.6 (4.4) 26.8 (5.2) 0.38 27.3 (4.7) 27.9 (5.7) 26.1 (5.2) 0.16 27.0 (5.5) ‡ 
Years of Schooling (mean, SD) 11.7 (3.0) 11.2 (2.7) 0.41 11.5 (2.8) 11.4 (3.0) 11.9 (2.9) 0.43 11.4 (2.9) 11.5 (2.9) 11.8 (3.1) 0.68 11.6 (3.0) 
Respiratory Symptoms (n, %)            
Cough 35.0 (52.2) 25.0 (49.0) 0.73 60.0 (50.8) 32.0 (45.1) 18.0 (37.5) 0.41 50.0 (42.0) 16.0 (42.1) 13.0 (37.1) 0.66 29.0 (39.7) 
Phlegm 28.0 (41.8) 15.0 (29.4) 0.17 43.0 (36.8) 29.0 (40.8) 13.0 (27.1) 0.12 42.0 (35.3) 14.0 (36.8) 8.0 (22.8) 0.19 22.0 (30.1) 
Wheeze in last 12 months 31.0 (46.3) 23.0 (45.1) 0.90 54.0 (45.8) 43.0 (60.6) 26.0 (54.2) 0.49 69.0 (58.0) 19.0 (50.0) 18.0 (51.4) 0.90 37.0 (50.7) 
Dyspnoea on exertion 15.0 (23.8) 17.0 (34.0) 0.23 32.0 (27.4) 21.0 (31.8) 22.0 (46.8) 0.11 43.0 (38.1) 9.0 (24.3) 11.0 (34.4) 0.36 32.0 (28.3) 
Smoking History              
Age started (mean, SD) 16.4 (3.0) 17.6 (4.2) 0.06 16.9 (3.6) 18.1 (4.7) 17.7 (4.2) 0.63 18.0 (4.5) 20.3 (7.7) 19.3 (6.7) 0.55 19.8 (7.2) ‡ 
Cigarettes/day (median, IQR) 
20.0 (10.0, 
25.0) 
12.0 (5.0, 
20.0) 
0.02 
† 
16.7 (7.0, 
25.0) * 
20.0 (12, 25) 
15.0 (10.0, 
20.0) 
0.04 
† 
20.0 (10.0, 
25.0) 
13.5 (5.0, 
20.0) 
10.0 (7.0, 
15.0) 
0.55 
10.0 (6.0, 
20.0) 
Pack-Years (median, IQR) 
30.2 (18.0, 
47.2) 
21.4 (5.5, 
38.9) 
0.01 
† 
26.8 (12.2, 
45.5) * 
30.4 
(18.7,44.3) 
24.3 (14.2, 
41.1) 
0.17 
28.0 (17.2, 
41.6) 
20.0 (8.2, 
46.3) 
17.2 (10.1, 
24.9) 
0.37 
18.1 (8.7, 
37.4) ‡ 
Quit Activity (n, %)             
Physician quit advice 52.0 (78.8) 32.0 (64.0) 0.08 84.0 (72.4) 55.0 (20.3) 35.0 (74.5) 0.51 90.0 (77.6) 28.0 (73.7) 25.0 (71.4) 0.83 53.0 (72.6) 
₴ Advice in last 12 mo 11.0 (21.2) 6.0 (18.8) 0.79 
17.0 (20.2) 
* 
22.0 (40.0) 13.0 (37.1) 0.79 35.0 (38.9) 15.0 (53.6) 11.0 (44.0) 0.49 
26.0 (49.1) 
‡ 
₴,ꬸ Quit medication  17.0 (32.7) 18.0 (56.2) 
0.03 
† 
35.0 (41.7) 
* 
29.0 (52.7) 18.0 (51.4) 0.90 47.0 (52.2) 18.0 (64.3) 15.0 (60.0) 0.75 33.0 (62.3) 
Quit attempts ≥ 24 h in last 12 mo 
(median, IQR) 
0 (0, 1.0) 0 (0, 2.0) 0.54 0 (0, 1.0) * 1.0 (0, 2.0) 0.5 (0, 2.7) 0.98 1.0 (0, 2.0) 
2.0 (1.0, 
10.0) 
5.0 (0, 
12.0) 
0.55 3.0 (1, 11) 
* Fisher’s Exact Test; all bolded numbers are significant, † significant gender difference, within Stages of Change (p < 0.05); ‡ significant difference between Stages of Change 
(p < 0.05); ₴ a subset of those that responded to receiving physician advice; ꬸ prescribed or not * significant trend across Stages of Change (p < 0.05); mo—months, IQR—
inter quartile range, SD – standard deviation.  
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35.0 (41.7) 
* 
29.0 (52.7) 18.0 (51.4) 0.90 47.0 (52.2) 18.0 (64.3) 15.0 (60.0) 0.75 33.0 (62.3) 
Quit attempts ≥ 24 h in last 12 mo 
(median, IQR) 
0 (0, 1.0)  0, 2.0) 0.54 0 (0, 1.0) * 1.0 (0, 2.0) 0.5 (0, 2.7) 0.98 1 0 (0, 2.0) 
2.0 (1.0, 
10.0) 
5.0 (0, 
12.0) 
0.55 3.0 (1, 11) 
* Fisher’s Exact Test; all bolded numbers are significant, † significant gender difference, within Stages of Change (p < 0.05); ‡ significant difference between Stages of Change 
(p < 0.05); ₴ a subset of those that responded to receiving physician advice; ꬸ prescribed or not * significant trend across Stages of Change (p < 0.05); mo—months, IQR—
inter quartile range, SD – standard deviation.  
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Table 1. Demographics, Respiratory and Smoking Characteristics by Stages of Change and Gender, Burden of Obstructive Lung Diseases (BOLD)-Australia Study. 
Characteristics 
Stages of Change 
Pre-Contemplation (n = 118) Contemplation (n = 119) Preparation (n = 73)
M F p All M F p All M F p All 
Age (mean, SD) 54.9 (10.0) 53.1 (10.2) 0.35 54.1 (10.1) 52.4 (8.6) 55.1 (9.6) 0.12 53.5 (9.1) 53.9 (11.2  52.0 (8.4) 0.42 53.0 (10.0) 
BMI (mean, SD) 25.1 (4.2) 26.3 (5.1) 0.15 25.6 (4.6) 27.6 (4.4) 26.8 (5.2) 0.38 27.3 (4.7) 27.9 (5.7) 26.1 (5.2) 0.16 27.0 (5.5) ‡ 
Years of Schooling (mean, SD) 11.7 (3.0) 11.2 (2.7) 0.41 11.5 (2.8) 11.4 (3.0) 11.9 (2.9) 0.43 11.4 (2.9) 11.5 (2.9) 11.8 (3.1) 0.68 11.6 (3.0) 
Respiratory Symptoms (n, %) 
Cough 35.0 (52.2) 25.0 (49.0) 0.73 60.0 (50.8) 32.0 (45.1) 18.0 (37.5) 0.41 50.0 (42.0) 16.0 (42.1) 13.0 (37.1) 0.66 29.0 (39.7) 
Phlegm 28.0 (41.8) 15.0 (29.4) 0.17 43.0 (36.8) 29.0 (40.8) 13.0 (27.1) 0.12 42.0 (35.3) 14.0 (36.8) 8.0 (22.8) 0.19 22.0 (30.1) 
Wheeze in last 12 months 31.0 (46.3) 23.0 (45.1) 0.90 54.0 (45.8) 43.0 (60.6) 26.0 (54.2) 0.49 69.0 (58.0) 19.0 (50.0) 18.0 (51.4) 0.90 37.0 (50.7) 
Dyspnoea on exertion 15.0 (23.8) 17.0 (34.0) 0.23 32.0 (27.4) 21.0 (31.8) 22.0 (46.8) 0.11 43.0 (38.1) 9.0 (24.3) 11.0 (34.4) 0.36 32.0 (28.3) 
Smoking History 
Age started (mean, SD) 16.4 (3.0) 17.6 (4.2) 0.06 16.9 (3.6) 18.1 (4.7) 17.7 (4.2) 0.63 18.0 (4.5) 20.3 (7.7) 19.3 (6.7) 0.55 19.8 (7.2) ‡ 
Cigarettes/day (median, IQR) 
20.0 (10.0, 
25.0) 
12.0 (5.0, 
20.0) 
0.02 
†
16.7 (7.0, 
25.0) * 
20.0 (12, 25) 
15.0 (10.0, 
20.0) 
0.04 
†
20.0 (10.0, 
25.0) 
13.5 (5.0, 
20.0) 
10.0 (7.0, 
15.0) 
0.55 
10.0 (6.0, 
20.0) 
Pack-Years (median, IQR) 
30.2 (18.0, 
47.2) 
21.4 (5.5, 
38.9) 
0.01 
†
26.8 (12.2, 
45.5) * 
30.4 
(18.7,44.3) 
24.3 (14.2, 
41.1) 
0.17 
28.0 (17.2, 
41.6) 
20.0 (8.2, 
46.3) 
17.2 (10.1, 
24.9) 
0.37 
18.1 (8.7, 
37.4) ‡ 
Quit Activity (n, %) 
Physician quit advice 52.0 (78.8) 32.0 (64.0) 0.08 84.0 (72.4) 55.0 (20.3) 35.0 (74.5) 0.51 90.0 (77.6) 28.0 (73.7) 25.0 (71.4) 0.83 53.0 (72.6) 
₴ Advice in last 12 mo 11.0 (21.2) 6.0 (18.8) 0.79 
17.0 (20.2) 
* 
22.0 (40.0) 13.0 (37.1) 0.79 35.0 (38.9) 15.0 (53.6) 11.0 (44.0) 0.49 
6.0 (49.1) 
‡
₴,ꬸ Quit medication 17.0 (32.7) 18.0 (56.2) 
0.03 
†
35.0 (41.7) 
* 
29.0 (52.7) 18.0 (51.4) 0.90 47.0 (52.2) 18.0 (64.3) 15.0 (60.0) 0.75 33.0 (62.3) 
Quit attempts ≥ 24 h in last 12 mo 
(median, IQR) 
0 (0, 1.0) 0 (0, 2.0) 0.54 0 (0, 1.0) * 1.0 (0, 2.0) 0.5 (0, 2.7) 0.98 1.0 (0, 2.0) 
2.0 (1.0, 
10.0) 
5.0 (0, 
12.0) 
0.55 3.0 (1, 11) 
* Fisher’s Exact Test; all bolded numbers are significant, † significant gender difference, within Stages of Change (p < 0.05); ‡ significant difference between St ges of 
Change (p < 0.05); ₴ a subset of those that responded to receiving physician advice; ꬸ prescribed or not * significant trend across Stages of Change (p < 0.05); mo—months, 
IQR—inter quartile range, SD – standard deviation.
Q it medication 17.0 (32.7) 18.0 (56.2) 0.03 † 35.0 (41.7) * 29.0 (52.7) 18.0 (51.4) 0.90 47.0 (52.2) 18.0 (64.3) 15.0 (60.0) 0.75 33.0 (62.3)
Quit attempts ≥ 24 h in last 12
mo (median, IQR) 0 (0, 1.0) 0 (0, 2.0) 0.54 0 (0, 1.0) * 1.0 (0, 2.0) 0.5 (0, 2.7) 0.98 1.0 (0, 2.0) 2.0 (1.0, 10.0) 5.0 (0, 12.0) 0.55 3.0 (1, 11)
* Fisher’s Exact Test; all bolded numbers are significant, † significant gender difference, within Stages of Change (p < 0.05); ‡ significant difference between Stages of Change (p < 0.05);
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Some associations are reported in Table 1 for when participants’ smoking history by SoC and
gender were examined. The mean difference observed in starting age of smoking across the stages
(F2,307 = 7.56, p = 0.001) with those in the preparation stage starting at an older age than those in
contemplation and pre-contemplation (p = 0.04 and p < 0.001 respectively). However, within each stage,
there was no significant difference between males and females for the age at which they started smoking.
Based on the number of cigarettes smoked per day, males were heavier smokers than females in the
pre-contemplation and contemplation stages (U = 1269, p = 0.02 and U = 1330, p = 0.04). The amount
smoked in pack-years also appeared greater in men but this was only statistically significant in the
pre-contemplation stage (U = 1231, p = 0.01). The median number of cigarettes smoked differed across
the three stages (χ22,310 = 9.4, p = 0.01); those in the preparation stage smoked less than those in
contemplation (p = 0.002) and pre-contemplation (p = 0.03).
No gender or SoC differences were observed in smokers who received quit advice from a
health professional. However, across the SoC, more participants in contemplation and preparation
stages had received advice within the previous 12 months compared to those in pre-contemplation
(χ22,227 = 13.3, p = 0.001). There was a linear trend for participants to receive advice in later stages
(p < 0.001). Additionally, of those who ever received quit advice, more females than males in the
pre-contemplation stage used some form of medication to stop smoking (χ21, 84 = 4.5, p= 0.03). While no
significant difference in use of medication observed across the stages (χ22,227 = 5.7, p = 0.06), there was
a significant linear trend (p = 0.02). For quit attempts lasting a minimum of 24 hours in the previous
year, there was a significant difference between individuals’ SoC (χ22,309 = 5.7, p < 0.001), with most
occurring in the preparation compared to contemplation stage (p < 0.001) and in the contemplation
compared to the pre-contemplation stage (p = 0.01); no gender differences were observed within
the SOC.
3.2. Decisional Balance and Stages of Change
In Table 2, there were no differences between males and females for the mean DB scores or the
pro and con scores were observed. Examining individual responses related to the pro and con items,
females had significantly higher scores when reporting smoking relieved tension (t253 = 2.7, p = 0.01)
and that they were embarrassed to have to smoke (t253 = 2.2, p = 0.03).
Table 2. Decisional Balance and Response Items by Gender, BOLD-Australia Study.
Decisional Balance
Male (n = 143) Female (n = 112) p
Mean SD Mean SD
Pro Score † 7.0 2.7 7.6 2.9 0.11
Concentration Improved ‡ 1.8 1.1 1.8 1.2 0.94
Relaxed and Pleasant 2.5 1.1 2.7 1.3 0.28
Tension Relief 2.7 1.2 3.1 1.2 0.01
Con Score 8.7 3.6 9.4 3.4 0.10
Bothers Others 3.4 1.4 3.5 1.3 0.51
Embarrassed 2.2 1.4 2.6 1.5 0.03
Foolish 3.1 1.6 3.3 1.5 0.24
Balance Score −1.7 4.4 −1.9 3.7 0.72
† Range for Scores: 3–15; ‡ Items based on a 5-point Likert response scale; significant values in bold.
On examining the relationship between DB and SoC, there were no gender differences observed for
mean DB pro and con scores within each SoC stage. However, males displayed significant differences
across the SoC for the DB cons score (F2,138 = 11.3, p < 0.001) and DB balance score (F2,138 = 7.4,
p = 0.001). This was most noticeable amongst those in the contemplation and preparation stage,
having greater aggregate scores when compared to those in pre-contemplation (ps < 0.0001) for the DB
cons and similarly for the DB balance (p = 0.004 & p = 0.003 respectively). Females only displayed
a significant difference across the stages for the cons (F2,108 = 6.9, p = 0.002); particularly between
Int. J. Environ. Res. Public Health 2019, 16, 3372 7 of 12
pre-contemplation and contemplation (p = 0.003) and pre-contemplation and preparation (p = 0.014).
Additionally, there were more negative than positive attitudes towards smoking, primarily in the
contemplation and preparation stages. Only the cons showed a significant difference in mean scores
between the stages (F2,249 = 17.3, p < 0.001), with those in the contemplation and preparation stages
reporting significantly more negative attitudes towards smoking than those in pre-contemplation
(ps < 0.001). The balance of the pros and the cons showed an increasing trend in negative over positive
attitudes toward smoking across the SoC (F2,249 = 9.2, p < 0.001).
3.3. Factors Associated with Readiness to Quit in Smokers
Table 3 presents the main independent effects of the variables entered into multivariable logistic
regression models with the ORs showing the increased odds of a smoker being in a particular stage
of change.
Table 3. Smokers in Pre-contemplation Stage versus Contemplation and Preparation Stage of Smokers,
BOLD-Australia Study.
Characteristics
Pre-Contemplationvs.
Contemplation Preparation
OR 95% CI OR 95% CI
Age started smoking 1.20 1.05, 1.38 1.39 1.19, 1.62
Con Score 1.35 1.17, 1.55 1.32 1.12, 1.56
Quit smoking at least 24 h in last 12 month 1.11 0.97, 1.26 1.14 0.99, 1.30
Quit medication used 2.21 0.94, 5.20 6.15 1.99, 19.02
Quit advice in last 12 month 3.35 1.31, 8.56 4.45 1.47, 13.49
n = 248 used for this analysis; OR – odds ratio; CI – confidence interval; significant values in bold.
Quitting smoking for at least 24 h in the last 12 months was not a significant predictor. Those who
had ever used some form of quit medication were more likely to be in the preparation stage compared
to pre-contemplation and those provided with quit advice in the last 12 months were more likely to be
in the contemplation and preparation stages than pre-contemplation. When the starting age increased
by one year, smokers were 20.0% more likely to be in the contemplation stage and 39.0% more likely to
be in the preparation stage than the pre-contemplation stage. DB showed that for every unit decrease
in the con score, smokers were 35.0% more likely to be in contemplation and 32.0% in preparation than
the pre-contemplation stage.
4. Discussion
In this study, we found being older (19 or 20 years) when starting smoking, using prescribed
or over the counter cessation medications, receiving advice on cessation within a 12-month period
and having more negative attitudes toward smoking were predictors of smokers contemplating or
preparing to quit. Smokers preparing to quit tended to decrease their daily cigarette intake, increase
their attempts at quitting (in the previous 12 months), received a higher frequency of cessation advice
and used more cessation medications. Overweight and obese smokers were typically contemplating or
preparing to quit. Gender differences observed were related to smoking history but were generally
not prominent.
4.1. Predicting a Smokers Readiness to Quit
Smoking remains a major risk factor in Australia despite a decrease in smoking prevalence.
In particular, the decline plateaued between 2013 and 2016 [6]; so it is important to continue work on
reducing prevalence. We aimed to identify predictors of readiness to change in Australian smokers.
These identified predictors could likely be utilised in technology-based health-related cessation tools as
interventions that delay the start of early smoking among adolescents to improve likelihood of quitting
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at a later stage with the aid of medication and appropriate messaging. Health promotion and counselling
programmes must remain dynamic, to effect behaviour change and integrate new findings related
to stages of change may contribute to cessation efforts. The advent of online or e-tools with readily
available health-related information changes the doctor-patient and healthcare-patient relationship;
empowering patients to be more involved in the decision process [25]. Pre-determining a smoker’s
readiness may be useful in building tailored cessation messages or programmes. This should also
be incorporated when developing or updating health promotion messages using health-gain-framed
statements. Interventions that at least delay the onset of smoking by adolescents may increase their
likelihood of later quitting.
4.2. Stages of Change and Decisional Balance
Decisional balance weighs positive and negative aspects related to problem behaviours and
then determines the importance of carrying out an action. Our study was fairly consistent with
other studies, where the balance between the pros and cons of behaviour towards smoking varied
according to the stage that a smoker occupied with change typically occurring in the contemplation
and preparation stages [26–29]. Smokers did not seem to place much importance on the positives
or negatives of smoking during the pre-contemplation stage but moving toward preparation there
was greater endorsement of the negative effects associated with smoking behaviour. Essentially,
the negatives of smoking were associated with smokers being likely to contemplate or prepare to quit;
consistent with previous studies [26–28].
The importance of reinforcing the negative effects of smoking as a potential mechanism for driving
smokers towards preparation provides support for current population health initiatives. The healthcare
providers’ role is that of supporter and reinforcer but every opportunity should be taken to give
cessation counsel, advice and follow-up whenever a smoker visits a health facility as few smokers visit
specifically for a smoking complaint.
4.3. Stages of Change and Demographic and Health Characteristics
Findings were largely consistent with previous studies, with our stage distributions of the SoC
being close to the theoretical expectation of 40-40-20 for PC-C-P, demonstrating most smokers are
in the early stages [11,26,30]. This expectation was based primarily on US studies of population
samples over 18 years of age and remains similar for those 40–64 years. Like the BOLD-US and other
studies [5,31], gender did not play a role in stage distribution nor with the other key demographics and
respiratory symptoms. European studies generally described a different distribution, 70-20-10, leaning
more to the pre-contemplation stage [9]. However our stage distribution was different from other
BOLD studies, which used similar methodology and age range and different from other Australian
studies [11,14,30,32].
Borland and Balmford [19], applying a perspective-based TTM to Australian smokers, aged 18 to
40 years, found a 48-38-19 distribution while a randomised control trial reported a 11-54-45 distribution
among smokers calling into the Victorian Quitline counselling service. Campbell et al. [32], found a
stage distribution of 40-43-14 in indigenous Australians 15 years and older. Dissimilarities are likely
related to population characteristics, smoking prevalence, policies, health promotion programmes
and/or real differences in smokers’ readiness to quit. This part of the Australian BOLD study focused
on non-indigenous smokers over 40 years old. Despite uncertainties around the use of the TTM,
Borland and Balmford [19] and others have shown that the TTM is still applicable.
In Australia there has been a steady decline in smoking prevalence since 1995, which apart from
smoking becoming increasingly unsociable, is associated with numerous mass media campaigns,
increased taxes and plain packaging laws to discourage smoking and increase quitting [3]. Both Sweden
and Iceland have also introduced laws and bans (between 2005 and 2007) on smoking in public places
and restrictions on advertising and packaging [11,33]. However Kentucky (USA) does not have
stringent anti-smoking campaigns, policies or enforce laws on advertising bans and taxes [34].
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Similar to BOLD-Scandinavia, we found an association between body mass index and SoC [11],
showing that overweight and obese smokers were contemplating or preparing to quit. Overweight
and obesity is a global problem which, over the last two decades, has increased among Australian
adults from 57% in 1995 to 63% in 2015 (36% overweight and 28% obese) [6]. Studies have found an
increased risk of obesity among smokers, in addition to which as leading causes of chronic diseases,
the combined effects could lead to worsening of conditions [35,36]. Changes in pulmonary function
are also related to central obesity [37]. For healthcare providers, knowledge of presence of obesity
or overweight among smokers is an additional indicator of likely lung function problems from the
combined effects of these conditions [37]. Losing weight may be a good public health messages to
incentivise improved lung function through quitting. However, there is a conundrum of smoking
cessation also being associated with weight gain. Health providers and health promotion should be
more aggressive in the presence of these combined risk factors and provide combined weight loss and
tobacco messaging and treatments.
4.4. Stages of Change by Smoking History
The study indicates that the smoking history factors associated with readiness to quit were
consistent with other studies, including BOLD [11,22,26,30,31,38].
Some smoking features also differed by gender with male pre-contemplators and contemplators
consuming more cigarettes and more females using some form of quit medication when they were
pre-contemplating. Young and Ward highlighted that Australian physicians were more likely to discuss
smoking with male patients [39]. It was unclear if this resulted from men, because they smoke more,
being more highly addicted and therefore should be encouraged to use quit aids like pharmacotherapy.
Despite smoking being more predominant among males, with the morbidity of conditions related to
tobacco smoking, clinicians should emphasize cessation to both genders. The Royal Australian College
of General Practitioners(GP) guidelines note the important contribution that health professionals can
make in cessation programmes by simply offering advice and assistance with quitting [40]. With over
80% of visits to a GP (or family/primary care physician), in a given year, their role in primary care
smoking prevention is very important [41]. GPs identify approximately two thirds of smokers but only
provide cessation advice to approximately half [42].
4.5. Strengths and Limitations
The main strength underlying these results is that the data are from a nationwide population
sample [21]. The large sample of the main study allowed for reasonable estimates based on objective
measures and the use of standardised definitions. The protocol and questionnaires were harmonised
with the BOLD international protocol allowing for country comparisons [43].
However, this study is not without limitations. For example, the exclusion of one study site due
to missing data may have an impact on the decisional balance analysis, despite their similar profile.
Results should only be generalised to those aged ≥40 years and some participants may have provided
answers deemed socially desirable. There may be some self-reporting bias and misclassification on the
participant’s actual readiness to quit. Additionally, this study is cross-sectional, preventing inferences
related to changes over time in TTM constructs.
5. Conclusions
In this study of 314 current smokers from the BOLD-Australia Study, we found quit attempts were
more common among those preparing to quit while smoking advice and cessation medication decreased.
Smokers displayed a range of common symptoms such as cough, phlegm wheeze and dyspnoea.
Gender did not play a major role impacting SoC or DB but males received more advice on quitting in
the preparation stages, while females used more cessation medications when pre-contemplating. The
factors identified are modifiable and could be used by healthcare providers for cessation programmes;
evaluating overweight/obese and using it to incentivise cessation, nudging smokers along the path to
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cessation with continued reinforcement of the negative impact of smoking while highlighting health
gains. Progression through stages of change is not linear so re-evaluation of smoking behaviours and
readiness to quit is important. Future research is needed to look at the comorbid link between obesity
and smoking, two major modifiable risk factors, on cessation.
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